A Phase 2 interventional study of BMN 165 (rAvPAL-PEG) in Phenylketonuria, sponsored by BioMarin Pharmaceutical. Completed at 6 sites in United States. Open to participants aged 16 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-08-06.
Sponsored by BioMarin Pharmaceutical · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing pegvaliase in Phenylketonurias — 1 open to participants now, 2 under way, 1 of them phase 3. pegvaliase · Phenylketonurias.
Among the 10 studies testing pegvaliase in Phenylketonurias, this one is the 8th largest by enrollment, is the only one that started in 2012, is one of 4 in phase 2, and was the 5th registered.
191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.
Browse Phenylketonurias studies →1 of the 10 studies testing pegvaliase in Phenylketonurias is open now, in 1 country. Recruiting first, the newest first:
BioMarin Pharmaceutical · Sites in United States
Ages 18–65
By country, each count listing its studies:
pegvaliase: first FDA approval 2018 (PALYNZIQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.
This study: 16 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2012.
This study's enrollment of 24 is below the median of 27 across 122 interventional studies indexed under Phenylketonurias.
Median enrollment 39 across the 10 interventional studies. Of the 8 that completed or were terminated, 7 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 1 most frequent:
BioMarin Pharmaceutical is the lead sponsor of 112 studies on the registry; 13 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 12 (63%) have results posted.
35 studies in Phenylketonurias by BioMarin Pharmaceutical: 3 open now, 5 under way, 1 of them phase 3. Of 29 finished, 17 (59%) have results posted.
Among the 35 studies in Phenylketonurias by BioMarin Pharmaceutical, this one is the 21st largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 9 in phase 2, and was the 20th registered.
BioMarin Pharmaceutical’s Phenylketonurias studies by the year they started, since 2004.
1 of the studies testing pegvaliase in Phenylketonurias that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477691BioMarin PharmaceuticalImmune Modulation During Palynziq® Treatment in Adults (IMPALA) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing pegvaliase in Phenylketonurias, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BioMarin Pharmaceutical’s 35 in Phenylketonurias:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of dosing regimens of multiple subcutaneous (SC) doses of rAvPAL-PEG to induce an early and sustained Phe reduction while decreasing the frequency and severity of hypersensitivity reactions in patients with PKU.
The primary rationale for this study is to define an optimal rAvPAL-PEG dose regimen by establishing the therapeutic effect within the shortest time possible time for induction, titration and maintenance phases while reducing the severity and frequency of hypersensitivity reactions that may lead to dose interruptions. It is hypothesized that these goals can be achieved by keeping rAvPAL-PEG doses low when anti-PEG IgM response is predicted to be high and titrating to an efficacious dose once the IgG response to PAL has developed. Further investigation is needed to determine how early and quickly patients can titrate safely to lower blood Phe; therefore, this protocol proposes to assess two Groups using an induction/titration and maintenance schedule with an aim towards establishing the therapeutic effect safety within an optimal period of time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A diagnosis of PKU, with the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
4-8 week induction of rAvPAL-PEG at 2.5 mg, followed by titration to maintenance dose
Biological: BMN 165 (rAvPAL-PEG)
Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
Also known as: Recombinant Anabaena variabilis phenylalanine ammonia lyase
Blood Phenylalanine Concentration
All patients will have their plasma Phenylalanine (Phe) assessed. Please note that "Pharmacokinetics Sub-study" was not performed, and thus no results are available.
Time frame: Baseline, Week 24
Number of Participants With Study Drug Related Adverse Events
Time frame: Minimum Weekly Assessment of Injection Sites, Vital Signs and Adverse Events. Other Safety Assessments will be performed at other intervals (below):
Percentage of Participants With Positive Anti-PAL Immunoglobulin G [IgG]
Antibody Positivity
Time frame: Baseline, Week 24
Trough Concentration of BMN 165
PK assessment from pre-dose blood draw.
Time frame: Week 1, Week 24
Percentage of Participants With Positive Anti-PEG IgG
Antibody Positivity
Time frame: Baseline, Week 24
Percentage of Participants With Positive PAL-IgM
Antibody Positivity
Time frame: Baseline, Week 24
Percentage of Participants With Positive Anti-PEG-IgM
Antibody positivity
Time frame: Baseline, Week 24
Percentage of Participants With Positive Neutralizing Antibodies [Nab]
Antibody positivity
Time frame: Baseline, Week 24
Percentage of Participants With Positive Anti-PAL-IgE Antibodies
Antibody positivity
Time frame: Baseline, Week 24
Percentage of Participants With Positive Anti-PAL-PEG IgE Antibodies
Antibody positivity
Time frame: Baseline, Week 24
| Milestone | BMN 165 (rAvPAL-PEG) |
|---|---|
| Started | 24 |
| Completed | 24 |
| Not completed | 0 |
All patients will have their plasma Phenylalanine (Phe) assessed. Please note that "Pharmacokinetics Sub-study" was not performed, and thus no results are available.
| umol/L | rAvPAL-PEG |
|---|---|
| Baseline | 1168.8 ± 290.98 |
| Week 24 | 617.6 ± 529.28 |
| Participants | rAvPAL-PEG |
|---|---|
| Number of Participants With Study Drug Related Adverse Events | 23 |
Antibody Positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 4.3 |
| Week 24 | 95.5 |
PK assessment from pre-dose blood draw.
| ng/mL | rAvPAL-PEG |
|---|---|
| Week 1 Day 1 | 0.2 ± 1.09 |
| Week 24 | 2341.1 ± 4768.28 |
Antibody Positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 26.1 |
| Week 24 | 22.7 |
Antibody Positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 34.8 |
| Week 24 | 90.9 |
Antibody positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 4.3 |
| Week 24 | 9.1 |
Antibody positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 0 |
| Week 24 | 27.3 |
Antibody positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 0 |
| Week 24 | 0 |
Antibody positivity
| percentage | rAvPAL-PEG |
|---|---|
| Baseline | 0 |
| Week 24 | 0 |
Collected over Week 0- Week 24. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rAvPAL-PEG | 0/24 (0%) | 1/24 (4.2%) | 23/24 (95.8%) |
| Event | rAvPAL-PEG |
|---|---|
| Blood creatine phosphokinase increasedInvestigations | 1/24 |
| Event | rAvPAL-PEG |
|---|---|
| Injection site reactionGeneral disorders | 18/24 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 18/24 |
| Injection site erythemaGeneral disorders | 13/24 |
| Injection site bruisingGeneral disorders | 10/24 |
| Upper respiratory tract infectionInfections and infestations | 9/24 |
| NauseaGastrointestinal disorders | 8/24 |
| Injection site rashGeneral disorders | 8/24 |
| RashSkin and subcutaneous tissue disorders | 8/24 |
| HeadacheNervous system disorders | 7/24 |
| PyrexiaGeneral disorders | 6/24 |
| Age, Continuous(years) | rAvPAL-PEG |
|---|---|
| Mean | 29.3 ± 11.43 |
| Age, Customized(Participants) | rAvPAL-PEG |
|---|---|
| < 18 years | 1 |
| > or = 18 years | 23 |
| Sex: Female, Male(Participants) | rAvPAL-PEG |
|---|---|
| Female | 13 |
| Male | 11 |
| Ethnicity (NIH/OMB)(Participants) | rAvPAL-PEG |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race/Ethnicity, Customized(Participants) | rAvPAL-PEG |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 24 |
| Other | 0 |
| Region of Enrollment(Participants) | rAvPAL-PEG |
|---|---|
| United States | 24 |
The record gives a start of May 2012, a primary completion of Sep 2013 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 5 years 5 months after primary completion. A results delay was requested in Aug 2017.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegvaliase